Arvinas Inc logo

ARVN - Arvinas Inc News Story

$67.16 -0.9  -1.2%

Last Trade - 05/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £2.40bn
Enterprise Value £1.90bn
Revenue £15.7m
Position in Universe 1781st / 6846

Arvinas to Participate in Upcoming Virtual Investor Conferences

Wed 10th March, 2021 9:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210310:nGNXbDWZVY&default-theme=true


NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq:
ARVN), a clinical-stage biotechnology company creating a new class of drugs
based on targeted protein degradation, today announced that it will
participate in two upcoming virtual investor conferences. John Houston, Ph.D.,
President and Chief Executive Officer, will participate in panel discussions
at both conferences.
* Guggenheim Targeted Protein Degradation Day panel discussion
(https://kvgo.com/guggenheim/arvinas-march-2021) on Tuesday, March 16, 2021 at
10:30 a.m. ET
* 33rd Annual Roth Conference panel discussion
(https://wsw.com/webcast/roth35/panel28/2116674) on Wednesday, March 17, 2021
at 5:00 p.m. ET
A live audio webcast of each panel will be available on Arvinas’ website at
www.arvinas.com. A replay of each webcast will be archived on Arvinas’
website for 30 days following the presentation.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving
the lives of patients suffering from debilitating and life-threatening
diseases through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC(®) Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC(®) targeted protein degraders, that are designed to
harness the body’s own natural protein disposal system to selectively and
efficiently degrade and remove disease-causing proteins. In addition to its
robust preclinical pipeline of PROTAC(®) protein degraders against validated
and “undruggable” targets, the company has two clinical-stage programs:
ARV-110 for the treatment of men with metastatic castrate-resistant prostate
cancer; and ARV-471 for the treatment of patients with locally advanced or
metastatic ER+/HER2- breast cancer. For more information, visit
www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations 
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com

(https://www.globenewswire.com/NewsRoom/AttachmentNg/01c438aa-c5bc-4cf7-aea3-ee40d0972b17)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.